TURNOVER (x1000 NOK)
NET PROFIT (x1000 NOK)
EMPLOYEES
Salipro Biotech AB
Closing information (x1000 NOK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
6,777
|
6,046
|
7,064 |
| Financial expenses |
1
|
1
|
0 |
| Earnings before taxes |
-4,694
|
-4,320
|
-2,276 |
| EBITDA |
-3,948
|
-3,757
|
-1,747 |
| Total assets |
11,134
|
15,824
|
18,564 |
| Current assets |
4,692
|
9,669
|
13,498 |
| Current liabilities |
1,507
|
1,756
|
1,394 |
| Equity capital |
9,627
|
14,068
|
17,169 |
| - share capital |
71
|
70
|
65 |
| Employees (average) |
8
|
9
|
7 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
86.5%
|
88.9%
|
92.5% |
| Turnover per employee |
847
|
672
|
1,009 |
| Profit as a percentage of turnover |
-69.3%
|
-71.5%
|
-32.2% |
| Return on assets (ROA) |
-42.2%
|
-27.3%
|
-12.3% |
| Current ratio |
311.3%
|
550.6%
|
968.3% |
| Return on equity (ROE) |
-48.8%
|
-30.7%
|
-13.3% |
| Change turnover |
622
|
-1,520
|
2,799 |
| Change turnover % |
10%
|
-20%
|
66% |
| Chg. No. of employees |
-1
|
2
|
1 |
| Chg. No. of employees % |
-11%
|
29%
|
17% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.